Terminated NA INTERVENTIONAL 3-arm NCT00794313

Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease

Sponsor: Oregon Health and Science University

Interventions Amantadine 300 mg Sugar Pill Topiramate

Updated 9 times since 2017 Last updated: Jan 8, 2018 Started: Sep 30, 2009 Primary completion: Jun 30, 2010 Completion: Jun 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Funding Ended

Other terminated trials from Oregon Health and Science University

See all terminations from Oregon Health and Science University

Other Parkinson's Disease trials with similar outcome

Browse all Parkinson's Disease trials

This NA trial investigates Parkinson's Disease and is currently terminated or withdrawn. Oregon Health and Science University leads this study, which shows 9 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Terminated NA
Jul 2024 — Sep 2024 [monthly]

Terminated NA
Jan 2023 — Jul 2024 [monthly]

Terminated NA
Dec 2022 — Jan 2023 [monthly]

Terminated NA
Jan 2021 — Dec 2022 [monthly]

Terminated NA

▶ Show 4 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated NA
Jul 2017 — Jun 2018 [monthly]

Terminated NA
Feb 2017 — Jul 2017 [monthly]

Terminated NA
Jan 2017 — Feb 2017 [monthly]

Terminated NA

First recorded

Sep 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Oregon Health and Science University

Data source: Oregon Health and Science University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Portland, United States